---
title: "J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM) — Share Price, Financials & Analysis"
symbol: "JBCHEPHARM"
company: "J B Chemicals & Pharmaceuticals Ltd"
canonical: "https://tapetide.com/stocks/JBCHEPHARM"
isin: "INE572A01036"
nse_symbol: "JBCHEPHARM"
bse_code: "506943"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T20:39:24.234Z"
---

# J B Chemicals & Pharmaceuticals Ltd (JBCHEPHARM)

Canonical page: https://tapetide.com/stocks/JBCHEPHARM

## Company

- **NSE Symbol:** JBCHEPHARM
- **BSE Code:** 506943
- **ISIN:** INE572A01036
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2003-04-29
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** jbpharma.com

## About

J.B. Chemicals and Pharmaceuticals Limited, established in 1976, is one of India's leading pharmaceutical companies. An integrated, publicly-listed organization with a focus on supplying affordable, quality products both in India and internationally, JBCPL is trusted by healthcare professionals globally. [1]

## Latest Price

- **Price:** ₹2408.9
- **Change:** 0 (0%)
- **Open:** ₹2506
- **Day High:** ₹2525.5
- **Day Low:** ₹2380
- **Previous Close:** ₹2408.9
- **Volume:** 0
- **As Of:** 2026-07-16T10:29:38+00:00

## Key Fundamentals

Observed at 2026-09-11T04:32:22.107248Z.

- **P/E (reported):** 0
- **P/E (TTM):** 53.33
- **EPS (TTM):** ₹45.17
- **EPS (reported):** ₹37.83
- **Book Value:** ₹0
- **Price to Book:** 0
- **Dividend Yield:** 0.91%
- **ROE:** 0%
- **ROCE:** 21.88%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹4207.9 Cr
- **Net Income:** ₹709.5 Cr
- **EBITDA:** ₹1167.6 Cr
- **52-Week High:** ₹2510
- **52-Week Low:** ₹1627
- **RSI (14):** 83.11

## Tapetide Score

- **Score:** 63 / 100
- **Score date:** 2026-07-14
- **Archetype:** Quality at a Reasonable Price
- **What it means:** Financial strength is not being paid for with a demanding multiple. The question worth asking is whether the quality is durable or reflects a good patch — check the consistency of returns over several years rather than the latest quarter.
- **Pillar profile:** Quality: Good · Valuation: Fair · Momentum: Rising
- **Percentile:** 92.9 (of 4243 scored stocks)
- **Confidence:** 96%
- **Data coverage:** 92%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 75.4 | 15% |
| growth | 31.67 | 15% |
| momentum | 86.68 | 15% |
| ownership | 59.47 | 10% |
| quality | 67.26 | 25% |
| valuation | 55.07 | 20% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 40.3%
- Promoter holding has increased by 1.25% over last quarter.

### Weaknesses

- Stock is trading at 9.30 times its book value
- Promoter holding has decreased over last 3 years: -5.11%
- Working capital days have increased from 86.6 days to 126 days

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -22% | -12.08% | 313.75% |
| ebitda margin growth | -40.82% | 2.59% | 4.6% | 17.34% |
| net income growth | -48.76% | 7.57% | 21% | 12% |
| revenue growth | -15.4% | 6.36% | 10% | 15% |
| roce | -49.43% | -11.38% | -14.06% | 22.94% |
| roe | -48.77% | -11.19% | 18.39% | -5.48% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 896 | 882 | 845 | 862 | 1004 | 1001 | 963 | 949 | 1094 | 1085 | 1065 | 904 |
| Expenses | 664 | 638 | 621 | 664 | 724 | 730 | 709 | 723 | 793 | 775 | 769 | 703 |
| Operating Profit | 232 | 244 | 223 | 198 | 280 | 271 | 255 | 226 | 301 | 310 | 296 | 201 |
| OPM % | 26 | 28 | 26 | 23 | 28 | 27 | 26 | 24 | 28 | 29 | 28 | 22 |
| Other Income | 6 | 8 | 7 | 17 | 6 | 10 | 8 | 14 | 15 | 15 | 18 | -15 |
| Interest | 12 | 10 | 12 | 9 | 6 | 2 | 3 | 1 | 1 | 1 | 2 | 1 |
| Depreciation | 31 | 32 | 34 | 41 | 41 | 42 | 42 | 46 | 43 | 44 | 45 | 50 |
| Profit before tax | 194 | 209 | 184 | 165 | 240 | 237 | 218 | 193 | 272 | 279 | 267 | 135 |
| Tax % | 27 | 28 | 27 | 23 | 26 | 26 | 25 | 25 | 25 | 26 | 26 | 25 |
| Net Profit | 142 | 151 | 134 | 126 | 177 | 175 | 162 | 146 | 202 | 208 | 198 | 101 |
| EPS in Rs | 9.19 | 9.72 | 8.62 | 8.13 | 11.39 | 11.24 | 10.45 | 9.36 | 12.96 | 13.27 | 12.63 | 6.31 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 1344 | 1408 | 1643 | 1775 | 2043 | 2424 | 3149 | 3484 | 3918 | 4148 |
| Expenses | 1112 | 1191 | 1337 | 1397 | 1482 | 1881 | 2454 | 2587 | 2886 | 3040 |
| Operating Profit | 232 | 218 | 306 | 378 | 560 | 543 | 696 | 897 | 1032 | 1107 |
| OPM % | 17 | 15 | 19 | 21 | 27 | 22 | 22 | 26 | 26 | 27 |
| Other Income | 50 | 37 | 41 | 41 | 112 | 39 | 10 | 37 | 38 | 33 |
| Interest | 5 | 3 | 5 | 3 | 7 | 5 | 36 | 44 | 12 | 6 |
| Depreciation | 47 | 57 | 56 | 66 | 69 | 73 | 114 | 138 | 171 | 182 |
| Profit before tax | 230 | 194 | 287 | 349 | 597 | 505 | 555 | 752 | 887 | 952 |
| Tax % | 20 | 28 | 32 | 22 | 25 | 24 | 26 | 26 | 26 | 26 |
| Net Profit | 184 | 139 | 194 | 272 | 449 | 386 | 410 | 553 | 660 | 709 |
| EPS in Rs | 10.85 | 8.27 | 12.06 | 17.6 | 28.98 | 24.93 | 26.48 | 35.61 | 42.36 | 44.18 |
| Dividend Payout % | 5 | 12 | 21 | 31 | 28 | 33 | 34 | 34 | 37 | 50 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 17 | 17 | 16 | 15 | 15 | 15 | 15 | 16 | 16 | 16 |
| Reserves | 1347 | 1425 | 1464 | 1420 | 1794 | 2119 | 2465 | 2908 | 3418 | 4143 |
| Borrowings | 49 | 29 | 26 | 29 | 45 | 55 | 572 | 378 | 28 | 4 |
| Other Liabilities | 262 | 294 | 286 | 349 | 376 | 412 | 495 | 687 | 804 | 799 |
| Total Liabilities | 1674 | 1765 | 1792 | 1814 | 2231 | 2601 | 3547 | 3988 | 4265 | 4962 |
| Fixed Assets | 679 | 640 | 621 | 651 | 634 | 1277 | 1901 | 2004 | 1968 | 1885 |
| CWIP | 4 | 17 | 15 | 16 | 26 | 19 | 55 | 76 | 63 | 74 |
| Investments | 411 | 434 | 457 | 403 | 678 | 13 | 206 | 388 | 345 | 765 |
| Other Assets | 580 | 674 | 699 | 743 | 894 | 1293 | 1385 | 1519 | 1889 | 2237 |
| Total Assets | 1674 | 1765 | 1792 | 1814 | 2231 | 2601 | 3547 | 3988 | 4265 | 4962 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 201 | 123 | 194 | 276 | 315 | 170 | 626 | 801 | 902 | 704 |
| Cash from Investing Activity | -45 | -21 | -28 | 24 | -231 | 2 | -962 | -404 | -296 | -586 |
| Cash from Financing Activity | -184 | -60 | -156 | -306 | -87 | -138 | 357 | -385 | -580 | -123 |
| Net Cash Flow | -28 | 43 | 11 | -6 | -3 | 34 | 20 | 11 | 27 | -5 |
| Free Cash Flow | 48 | 94 | 153 | 205 | 315 | -529 | -138 | 540 | 783 | 623 |
| CFO/OP | 107 | 75 | 85 | 97 | 81 | 56 | 104 | 104 | 107 | 87 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 72 | 78 | 68 | 71 | 70 | 84 | 67 | 72 | 76 | 69 |
| Inventory Days | 138 | 145 | 149 | 159 | 181 | 178 | 134 | 155 | 147 | 192 |
| Days Payable | 68 | 75 | 72 | 97 | 97 | 97 | 75 | 110 | 114 | 110 |
| Cash Conversion Cycle | 142 | 148 | 146 | 133 | 153 | 164 | 127 | 117 | 109 | 151 |
| Working Capital Days | 75 | 93 | 91 | 81 | 91 | 122 | 81 | 55 | 79 | 126 |
| ROCE % | 14 | 11 | 18 | 23 | 33 | 23 | 22 | 25 | 26 | 25 |

## Shareholding Pattern

### annual

| Category | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 55.76% | 55.84% | 56.02% | 55.91% | 55.91% | 54% | 53.93% | 53.78% | 47.84% | 48.8% |
| FIIs | 5.46% | 5.32% | 5.34% | 7.18% | 7.54% | 9.22% | 8.62% | 11.06% | 18.3% | 16.33% |
| DIIs | 9.46% | 12.75% | 15.82% | 14.56% | 13.17% | 16.89% | 19.08% | 18.38% | 18.71% | 21.38% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0.01% | 0% | 0% |
| Public | 29.32% | 26.1% | 22.82% | 22.35% | 23.38% | 19.89% | 18.35% | 16.78% | 15.13% | 13.48% |
| No. of Shareholders | 32069 | 34095 | 32429 | 35211 | 65718 | 61314 | 56633 | 63892 | 63948 | 74043 |

### Quarterly

| Category | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 53.91% | 53.86% | 53.83% | 53.78% | 53.77% | 53.74% | 53.66% | 47.84% | 47.73% | 47.56% | 47.55% | 48.8% |
| FIIs | 9.53% | 10.05% | 10.35% | 11.06% | 12.17% | 13.63% | 14.64% | 18.3% | 17.77% | 15.31% | 14.88% | 16.33% |
| DIIs | 18.65% | 18.58% | 18.53% | 18.38% | 17.61% | 16.81% | 16.4% | 18.71% | 19.62% | 22.83% | 23.35% | 21.38% |
| Government | 0% | 0% | 0% | 0.01% | 0% | 0.01% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 17.9% | 17.5% | 17.27% | 16.78% | 16.42% | 15.8% | 15.29% | 15.13% | 14.87% | 14.31% | 14.21% | 13.48% |
| No. of Shareholders | 55965 | 60817 | 63230 | 63892 | 66953 | 62743 | 62081 | 63948 | 70064 | 71957 | 69338 | 74043 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 12 / 4 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 2435.49 | Sell |
| EMA (10) | 2423.45 | Sell |
| SMA (20) | 2344.27 | Buy |
| EMA (20) | 2366.34 | Buy |
| SMA (50) | 2241.45 | Buy |
| EMA (50) | 2259.72 | Buy |
| SMA (100) | 2142.03 | Buy |
| EMA (100) | 2154.18 | Buy |
| SMA (200) | 1965.87 | Buy |
| EMA (200) | 2024.89 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 60.96 | Neutral |
| MACD (12,26,9) | 72.22 | Buy |
| Stochastic (14,3,3) | 85.68 | Sell |
| ADX (14) | 41.17 | Buy |
| Williams %R (14) | -40.32 | Neutral |
| ATR (14) | 59.79 | Neutral |
| ROC (12) | 4.92 | Buy |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 59.33 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-07-08 | [Intimation Of Effective Date Of Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=44d6ab2d-8a71-4750-a4a3-694f63dd0f38.pdf) |
| 2026-07-07 | [Receipt Of Certified Copy Of Order Passed By National Company Law Tribunal Ahmedabad Bench (NCLT) Regarding The Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=af428c95-c9a3-4a22-b945-ce08fd91855e.pdf) |
| 2026-07-07 | [Record Date For The Purpose Of Determining The Shareholders Of The Company Who Shall Be Entitled To Receive Fully Paid-Up Equity Shares Of Torrent Pharma As Per The Share Exchange Ratio](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8a6f1bbb-6e7d-41e6-a857-c6ef8a3c659d.pdf) |
| 2026-07-07 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8ee84423-2f65-49e7-9586-d8ea45b80852.pdf) |
| 2026-07-06 | [Pronouncement Of Final Order By The HonBle National Company Law Tribunal Ahmedabad Bench Sanctioning The Scheme Of Amalgamation Of J. B. Chemicals & Pharmaceuticals Limited With Torrent Pharmaceuticals Limited And Their Respective Shareholders](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b1b676f4-b659-4354-918b-07916bb68b45.pdf) |
| 2026-06-30 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e1f29004-028f-4e5a-a019-2e340ad2e00c.pdf) |
| 2026-06-30 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c8582c18-f834-498a-9e18-bdd264923452.pdf) |
| 2026-06-17 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4dacb560-4f34-416a-8a93-a8d38cc42b8e.pdf) |
| 2026-06-17 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1b8cc15e-8562-4881-ba6a-41d867e09704.pdf) |
| 2026-06-15 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9a5d487-740a-4601-b2af-8d0a72cd90f4.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-05-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7fe6d83c-f1bc-4506-bf4f-a4fb2de8a940.pdf) |
| 2026-01-19 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=42edf473-5fa8-4e9f-8f66-e0a26bd8ae38.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8a70ee3a-7834-4a64-861e-5510ce157d8e.pdf) |
| 2025-07-31 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=50d6e7fe-e3dc-438e-82c8-eeea32d233f0.pdf) |
| 2025-05-15 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=438ccaf4-b65f-4632-9c0b-53dfcb9c0a1c.pdf) |
| 2024-11-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef5cb180-8efb-4e94-aef0-36649656c835.pdf) |
| 2024-08-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9d40bafb-7332-4763-84fd-57ff603f09ad.pdf) |
| 2024-05-21 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6cd35df8-8197-4507-8fad-a46789bb34e3.pdf) |
| 2024-02-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e10547a4-a051-4f67-961a-fc1f29831a25.pdf) |
| 2023-12-22 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d1f5db76-0fce-488a-ac09-df0e8e93884d.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9h - Order dated 18-Mar-2026: INR 80,81,126 penalty (Section 74 GST) for Apr-2019–Mar-2020; company to appeal. | [Disclosure Under Regulation 30 Of The SEBI (LODR), Regulations, 2015 9h - Order dated 18-Mar-2026: INR 80,81,126 penalty (Section 74 GST) for Apr-2019–Mar-2020; company to appeal.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/28def981-bf66-44ce-82db-cdd8eabdcd4f.pdf) |
| 8h - Shareholders approved Aman Mehta as MD from Jan 21, 2026 for three years; three Torrent executives appointed directors. | [Appointment Of Directors 8h - Shareholders approved Aman Mehta as MD from Jan 21, 2026 for three years; three Torrent executives appointed directors.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/8f5b0955-9815-4fb2-a96a-78368bd9a3bb.pdf) |
| 8h - Postal ballot (Mar 24, 2026) approved Aman Mehta as Director and MD; three other directors appointed; ~81% turnout. | [Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 8h - Postal ballot (Mar 24, 2026) approved Aman Mehta as Director and MD; three other directors appointed; ~81% turnout.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2a7b902a-6376-4e6e-9d71-400f80cbc374.pdf) |
| 7 May - JB Pharma to host Q4 FY26 investor call on May 12, 2026; results on May 11. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7 May - JB Pharma to host Q4 FY26 investor call on May 12, 2026; results on May 11.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7fcb9097-d385-4f09-a496-c767d3e09a77.pdf) |
| 6h - JB Pharma reported Q4 FY26 revenue of Rs 904 crore, PAT Rs 101 crore, and FY26 revenue of Rs 4,148 crore. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 6h - JB Pharma reported Q4 FY26 revenue of Rs 904 crore, PAT Rs 101 crore, and FY26 revenue of Rs 4,148 crore.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/076259aa-c1dc-48dc-83ae-b3b1dd030935.pdf) |
| 6h - FY26 audited results approved; shareholders cleared Torrent merger; final dividend Rs 9.30/share recommended. | [Board Meeting Outcome for Outcome Of Board Meeting 6h - FY26 audited results approved; shareholders cleared Torrent merger; final dividend Rs 9.30/share recommended.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/4e281df9-72e0-461b-8fbb-fd81e552872c.pdf) |
| 6 Apr - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2c3de546-45a6-4dae-9750-4e61c80454f8.pdf) |
| 5h - Newspaper advertisement cutting of publication of Notice of hearing of Petition | [Announcement under Regulation 30 (LODR)-Newspaper Publication 5h - Newspaper advertisement cutting of publication of Notice of hearing of Petition](https://www.bseindia.com/xml-data/corpfiling/AttachLive/53e6d9c3-8ca5-44ef-be1d-332745b79469.pdf) |
| 5 May - Board meeting on May 11, 2026 to approve FY26 audited results and consider final dividend. | [Board Meeting Intimation for Meeting Of The Board Will Be Held On May 11, 2026 5 May - Board meeting on May 11, 2026 to approve FY26 audited results and consider final dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/0111ff3e-4998-4224-a3ca-110d0d344bb6.pdf) |
| 4h - Company confirms it is not a large corporate under SEBI debt securities circular. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 4h - Company confirms it is not a large corporate under SEBI debt securities circular.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/dabef7ed-dc10-4865-85dd-24f08c2088f5.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc2db954-76c9-466a-8dc5-2db0027ac5e5.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cc2db954-76c9-466a-8dc5-2db0027ac5e5.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cb65f5e4-bfb3-4b95-8a01-b5ea9a055fd4.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cb65f5e4-bfb3-4b95-8a01-b5ea9a055fd4.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8590650c-e36a-42b6-ae84-728a9f48f19a.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8590650c-e36a-42b6-ae84-728a9f48f19a.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fc27f9a1-4d46-4ac2-ad51-36976fdeb6c6.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=626a6cf7-2576-4c4d-b0ec-c696465c088c.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/626a6cf7-2576-4c4d-b0ec-c696465c088c.pdf) |
| May 2026 | [Concall - May 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/111af8c9-a196-4f77-8aaf-465cfe6562b1.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-01-16 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ca617db8-1cc0-4ddc-b545-f22a5147da9a.pdf) |
| 2025-11-11 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9c335f8-6bfd-42f9-9fe5-42d6804ef0a1.pdf) |
| 2025-07-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65369514-828b-4cb8-a706-9779c0eef3cb.pdf) |
| 2025-06-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=32b9db24-3169-46de-b169-406e7932b44b.pdf) |
| 2025-05-14 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=806c78c2-67e6-48ca-8ff3-82bd4e00da10.pdf) |
| 2025-02-04 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=29578ced-9b90-45a6-85ad-7b5da9e3b14b.pdf) |
| 2024-11-07 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=02427c52-5b7c-4bc1-870c-160be2a58b4d.pdf) |
| 2024-08-08 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=011aa108-b813-4029-9aef-c0004d4fb090.pdf) |
| 2024-05-17 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4553606b-eb05-4ab8-ad0b-fe27a0b20468.pdf) |
| 2024-02-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fbb52fb3-44ae-4f97-97bc-779fa3a06804.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/be26eea2-6319-4b01-9d7a-6ea10258883e.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dd5f6b22-121a-46ee-a934-79d48b8d00a8.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/28df5106-d74e-44a2-9fde-139e6b3c370d.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d6f9fc42-b212-4847-9a27-fca86f793ae6.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/506943/73945506943.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2025-05-14 | [Audited Standalone & Consolidated Financial Results For The Year Ended On March 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7563bee8-e089-47d0-bd87-0ad8ce728004.pdf) |
| 2025-02-04 | [Unaudited Financial Results For The Quarter Ended On December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=df7b44e6-51fb-4cbd-b386-26f2b05fc0a1.pdf) |
| 2024-05-17 | [Audited Standalone And Consolidated Financial Results -31/03/2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=74403e6e-f33b-4514-8202-003c81dc235a.pdf) |
| 2024-02-06 | [Unaudited Financial Results For The Quarter And Nine Months Ended On December 31, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7719f5ba-f363-4d1b-b095-e3282cee2dc7.pdf) |
| 2023-11-07 | [Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=aac50d59-9636-40f9-a688-ae8c634003fb.pdf) |
| 2023-05-24 | [Board Meeting Outcome for Outcome Of The Board Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14ba8b38-1603-4f51-a260-abdfcbc32c04.pdf) |
| 2023-02-08 | [Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors - Unaudited Financial Results For The Quarter Ended December 31, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2c82a3cc-32e9-43a9-88e1-e42fde11ed4b.pdf) |
| 2022-11-11 | [Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors - Unaudited Financial Results For The Quarter Ended September 30, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c2f95cd-acca-4731-b792-0d0afda57207.pdf) |
| 2022-08-04 | [Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors - Unaudited Financial Results For The Quarter Ended June 30, 2022](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2f6d1d05-697a-4b20-9630-af5023643e30.pdf) |
| 2022-05-26 | [Board Meeting Outcome for Outcome Of Meeting Of Board Of Directors](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=073c86d2-2098-41db-900a-bd6628560501.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2023-05-30 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7963d883-0d72-449a-aa5f-f5c0734c7b8b.pdf) |
| 2023-02-13 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5cc90ead-d36e-41e2-a1be-b23c2839e511.pdf) |
| 2022-11-18 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fc27f9a1-4d46-4ac2-ad51-36976fdeb6c6.pdf) |
| 2022-05-31 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62aed8bb-2cd2-497c-8f02-696594e42631.pdf) |
| 2021-08-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=04306bb6-6c0f-46fb-b2ec-a8f56be468bb.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T20:39:24.234Z.